CytRx Corporation – Product Pipeline Review – 2012 by GlobalMarketsDirect

VIEWS: 23 PAGES: 79

More Info
									   CytRx Corporation – Product Pipeline Review – 2012

                                                                                          Reference Code: GMDHC02243CDB
                                                                                                 Publication Date: MAY 2012




CytRx Corporation – Product Pipeline Review – 2012                                        GMDHC02243CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
CytRx Corporation – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 5
CytRx Corporation Snapshot .............................................................................................................................................................. 6
    CytRx Corporation Overview ......................................................................................................................................................... 6
    Key Information ............................................................................................................................................................................. 6
    Key Facts....................................................................................................................................................................................... 6
CytRx Corporation – Research and Development Overview .............................................................................................................. 7
    Key Therapeutic Areas .................................................................................................................................................................. 7
CytRx Corporation – Pipeline Review .............................................................................................................................................. 10
    Pipeline Products by Stage of Development ............................................................................................................................... 10
    Pipeline Products – Monotherapy ............................................................................................................................................... 11
    Pipeline Products – Combination Treatment Modalities .............................................................................................................. 12
CytRx Corporation – Pipeline Products Glance ................................................................................................................................ 13
    CytRx Corporation Clinical Stage Pipeline Products ................................................................................................................... 13
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 13
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 14
    CytRx Corporation – Early Stage Pipeline Products .................................................................................................................... 15
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 15
CytRx Corporation – Drug Profiles ................................................................................................................................................... 16
    Bafetinib ...................................................................................................................................................................................... 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
    INNO-206 .................................................................................................................................................................................... 18
        Product Description................................................................................................................................................................. 18
        Mechanism of Action ............................................................................................................................................................... 18
        R&D Progress ......................................................................................................................................................................... 18
    Iroxanadine .................................................................................................................................................................................. 20
        Product Description................................................................................................................................................................. 20
        Mechanism of Action ............................................................................................................................................................... 20
        R&D Progress ......................................................................................................................................................................... 20
    Paclitaxel + Carboplatin + Tamibarotene..................................................................................................................................... 22
    Paclitaxel + Carboplatin + Tamibarotene..................................................................................................................................... 22
        Product Description................................................................................................................................................................. 22
        Mechanism of Action ............................................................................................................................................................... 22
        R&D Progress ......................................................................................................................................................................... 22
    Tamibarotene .............................................................................................................................................................................. 24
        Product Description................................................................................................................................................................. 24
        Mechanism of Action ............................................................................................................................................................... 24
        R&D Progress ......................................................................................................................................................................... 24
CytRx Corporation – Pipeline Analysis ............................................................................................................................................. 26



CytRx Corporation – Product Pipeline Review – 2012                                                                                      GMDHC02243CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                       Page(2)
CytRx Corporation – Product Pipeline Review



    CytRx Corporation – Pipeline Products by Therapeutic Class ..................................................................................................... 26
    CytRx Corporation – Pipeline Products By Target ....................................................................................................................... 27
    CytRx Corporation – Pipeline Products by Route of Administration ............................................................................................ 28
    CytRx Corporation – Pipeline Products By Mechanism of Action ................................................................................................ 29
CytRx Corporation – Recent Pipeline Updates................................................................................................................................ 30
CytRx Corporation - Dormant Projects ............................................................................................................................................. 34
CytRx Corporation - Discontinued Pipeline Products ....................................................................................................................... 35
    Discontinued Pipeline Product Profiles ........................................................................................................................................ 35
        Arimoclomol ............................................................................................................................................................................ 35
        INNO-105 ................................................................................................................................................................................ 35
CytRx Corporation – Company Statement ....................................................................................................................................... 36
CytRx Corporation – Locations And Subsidiaries ............................................................................................................................. 39
    Head Office.................................................................................................................................................................................. 39
    Other Locations & Subsidiaries ................................................................................................................................................... 39
CytRx Corporation, Recent Developments ....................................................................................................................................... 40
    CytRx Corporation- Press Release.............................................................................................................................................. 40
        May 07, 2012: CytRx To Present Complete Clinical Data From INNO-206 Phase Ib/II Trial At American Society of Clinical
        Oncology ................................................................................................................................................................................. 40
        Apr 26, 2012: CytRx Initiates Phase II Clinical Trial With INNO-206 In Pancreatic Cancer .................................................... 41
        Apr 12, 2012: CytRx Announces Issuance Of Key US Patent Covering INNO-206 Linker Technology .................................. 42
        Mar 27, 2012: CytRx To Present Data On INNO-206 At AACR 2012 Annual Meeting ........................................................... 43
        Dec 07, 2009: CytRx Announces Positive Phase II Results Of Tamibarotene For The Treatment Of Relapsed Acute
        Promyelocytic Leukemia ......................................................................................................................................................... 44
        Nov 25, 2009: Cytrx Announces Plans To Initiate A Phase 2 Clinical Trial With Inno-206 In Patients With Advanced Soft
        Tissue Sarcomas .................................................................................................................................................................... 45
        Sep 14, 2009: CytRx Corporation Announces Initiation Of A Dose Escalation Study ....................................................... 46
        Jul 29, 2009: Preclinical Results Of CytRx Drug INNO-206 For Ovarian Tumor Shrinkage In Animal Trials. ........................ 46
        Jun 29, 2009: CytRx Reports Favorable Progress Update For Its Pivotal Phase 2 Clinical Trial With Tamibarotene As A
        Third-line Treatment For Acute Promyelocytic Leukemia ....................................................................................................... 48
        Jun 17, 2009: CytRx's Tamibarotene Demonstrates Statistically Significant Anti-Tumor Activity In Animal Trial For Multiple
        Myeloma ................................................................................................................................................................................. 48
Financial Deals Landscape .............................................................................................................................................................. 50
    CytRx Corporation, Deals Summary............................................................................................................................................ 50
CytRx Corporation, Pharmaceuticals & Healthcare, Deal Details..................................................................................................... 51
    Asset Transactions ...................................................................................................................................................................... 51
        CytRx Acquires Clinical And Pharma Assets From Biorex ...................................................................................................... 51
    Partnerships ................................................................................................................................................................................ 53
        CytRx Enters Into Research Agreement With University Of Massachusetts ........................................................................... 53
    Licensing Agreements ................................................................................................................................................................. 54
        CytRx Enters Into Licensing Agreement With The University of Massachusetts Medical School ........................................... 54
        CytRx Enters Into Licensing Agreement With Imperial College London ................................................................................. 55
    Equi
								
To top